Inability to return to Memorial Sloan-Kettering Cancer Center (MSKCC) for frequent scheduled hydration sessions post-chemotherapy
Histologically diagnosed metastatic cancer (diagnosis made or confirmed at Memorial Sloan-Kettering Cancer Center [MSKCC] for MSKCC participants; institutional pathologic determination accepted from participating multicenter sites)
Histological diagnosis of melanoma confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC)
Histologic proof of melanoma reviewed and confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC)
Diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the Memorial Sloan-Kettering [MSK] Department of Pathology) or bone marrow metastases plus high urine catecholamine levels
Confirmed tissue diagnosis of esophageal squamous cell cancer, adenocarcinoma or poorly differentiated carcinoma, with pathology reviewed at Memorial Sloan-Kettering Cancer Center (MSKCC)
Patients must have histologically confirmed MM by Memorial Sloan-Kettering Cancer Center (MSKCC) pathologist, with MM cells expressing BCMA, previously treated with + prior lines of therapy including an immunomodulatory imide drug (IMiD) and a PI, either with refractory, persistent, or progressive disease
PSA doubling time (PSADT) =<  months, based upon >=  consecutive measurements collected in the past  months, at least  weeks apart, calculating using the Memorial Sloan-Kettering Cancer Center (MSKCC) calculator
Diagnosis of NB as defined by a) histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSK] Department of Pathology), or b) BM metastases or metaiodobenzylguanidine (MIBG)-avid lesion(s) plus high urine catecholamine levels
As per self report, identifying as an informal caregiver to Memorial Sloan Kettering Cancer Center (MSKCC) patients of any site or stage of cancer
A diagnosis of dedifferentiated liposarcoma confirmed at Memorial Sloan Kettering Cancer Center (MSKCC)
Diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSKCC] Department of Pathology) or bone marrow metastases plus high urine catecholamine levels
The preoperative Memorial Sloan-Kettering (MSK) nomogram estimates the patients likelihood of freedom from metastatic recurrence within the first  years following radical or partial nephrectomy to be =< %
Patients must have recurrent OS; OS must be verified by histopathology review by the site's Department of Pathology; (patients registered at Memorial Sloan-Kettering Cancer Center [MSKCC] must have pathology confirmed by MSKCC Department of Pathology)
Patients must have histologic or cytologic proof of a non-hematologic malignancy confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) pathologic review
Patients must have a diagnosis of neuroblastoma (International Classification of Disease for Oncology [ICD-O] morphology /) confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) pathologic review
Previously untreated stage IV lung adenocarcinoma confirmed at the Memorial Sloan-Kettering Cancer Center (MSKCC)
Diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSKCC] Department of Pathology) or BM metastases plus high urine catecholamine levels
Symptomatic multiple myeloma, International Staging System (ISS) stage - with confirmed diagnosis of multiple myeloma at Memorial Sloan-Kettering Cancer Center (MSKCC)
Diagnosis of NB defined by a) histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSKCC] Department of Pathology), or b) bone marrow (BM) metastases or meta-iodobenzylguanidine (MIBG)-avid lesion(s) plus high urine catecholamine levels
Previous systemic anti-cancer therapy for T-cell lymphoma must have been discontinued at least  weeks prior to treatment; for the dose expansion phase, in progressing subjects, a  week washout may be allowed after discussion with Memorial Sloan-Kettering (MSK) principal investigator
Medical illness unrelated to Hodgkin lymphoma, which, in the opinion of the attending physician and/or Memorial Sloan Kettering (MSK) principal investigator, makes participation in this study inappropriate
Diagnosis of neuroblastoma (NB) as defined by international criteria, i.e., histopathology (confirmed by the Memorial Sloan-Kettering Cancer Center [MSKCC] Department of Pathology) or bone marrow metastases plus high urine catecholamine levels
Patients must have the diagnosis of NB in accordance with the international criteria, i.e., either histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSKCC] Department of Pathology) or bone marrow (BM) involvement plus elevated urinary catecholamines
The target tumor is limited to neuroblastoma and other GD-positive solid tumors; diagnosis should be histologically verified at Childrens Hospital of Michigan (CHM) or Memorial Sloan Kettering Cancer Center (MSKCC)
Morphologic confirmation of a diagnosis of AML or ALL at Memorial Sloan-Kettering Cancer Center (MSKCC)
Patients must have pathologically or cytologically Memorial Sloan-Kettering Cancer Center (MSKCC) confirmed diagnosis of gastric or GEJ adenocarcinoma
For the dose-escalation phase, a phosphatidylinositol-,-bisphosphate -kinase, catalytic subunit alpha (PIKCA) mutation is also required; Memorial Sloan-Kettering Cancer Center (MSKCC) or outside documentation is acceptable
Subjects with a history of coronary artery disease may be included if they have had a normal stress test within  days of enrollment and/or were cleared by Memorial Sloan Kettering (MSK) cardiology
Histologically confirmed high-grade upper tract transitional cell carcinoma at Memorial Sloan-Kettering Cancer Center (MSKCC) or a participating site and/or radiographically visible tumor stage T-Ta N/X M disease with positive selective urinary cytology; hydronephrosis associated with tumor on imaging or biopsy will be considered invasive by definition
Newly diagnosed or recurrent thymoma - World Health Organization (WHO) A, AB, B, B, or B or thymic carcinoma, pathologically confirmed at Memorial Sloan Kettering Cancer Center (MSKCC), MD Anderson Cancer Center (MDACC) or City of Hope
Confirmed histologic diagnosis of invasive adenocarcinoma of the breast, including Memorial Sloan-Kettering Cancer Center (MSKCC) pathology confirmation
Histologic confirmation of prostate cancer at Memorial Sloan-Kettering Cancer Center (MSKCC)
Diagnosis of NB as defined by international criteria i.e., histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSKCC] Department of Pathology) or bone marrow metastases plus high urine catecholamine levels
Histopathological documentation of prostate cancer confirmed in either the Laboratory of Pathology at the National Institutes of Health (NIH) Clinical Center, Walter Reed National Military Medical Center, Memorial Sloan Kettering Cancer Center (MSKCC), or Dana-Farber Cancer Institute (DFCI) or Beth Israel Deaconess Medical Center (BIDMC) prior to enrollment; if no pathologic specimen is available, patients may enroll with a pathologists report showing a histologic diagnosis of prostate cancer and a clinical course consistent with the disease
Previous systemic anti-cancer therapy must have been discontinued at least  weeks prior to treatment and adverse effects must have resolved to =< grade  or baseline; in the phase IIa portion, in progressing subjects, a  week washout may be allowed after discussion with the Memorial Sloan-Kettering (MSK) principal investigator
Locally and/or regionally advanced (M) head and neck squamous cell carcinoma (American Joint Committee on Cancer [AJCC] stage III-IVB), cytologically or pathologically confirmed by Department of Pathology at Memorial Sloan-Kettering Cancer Center (MSKCC), for which curative-intent radiation therapy is planned
Patients must have Memorial Sloan-Kettering Cancer Center (MSKCC) pathologically confirmed diagnosis of one of the following tumor types: \r\n* Ovarian, fallopian tube or primary peritoneal cancer\r\n* Ovarian carcinosarcoma\r\n* Endometrial cancer\r\n* Endometrial carcinosarcoma
Patients currently on the phase I trial combining perifosine + temsirolimus (Memorial Sloan-Kettering Cancer Center [MSKCC] Institutional Review Board [IRB] #-:  Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas; National Cancer Institute [NCI]-Cancer Therapy Evaluation Program #) who cannot continue treatment on the Phase I trial because of inadequate drug supply are eligible and will be continue being treated at the current dose they are receiving
Pathologically or cytologically Memorial Sloan-Kettering Cancer Center (MSKCC) confirmed esophagogastric adenocarcinoma
Patients with synovial sarcoma confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) pathological review
Memorial Sloan Kettering Cancer Center (MSKCC) pathologically-proven diagnosis of locally advanced stage III not amenable to definitive, curative treatment or stage IV or recurrent non-small cell lung cancer
Patients who are unwilling to consent to mandatory tumor biopsy; patients with archival tissue permitted to enroll on study per Memorial Sloan-Kettering (MSK) principal investigator discretion
Histological documented diagnosis of small cell lung cancer (SCLC) confirmed by a Memorial Sloan Kettering Cancer Center (MSKCC) pathologist.
Undergoing a laparotomy procedure via a vertical midline incision for any indication with the gynecology service at Memorial Sloan Kettering (MSK)
Histologically proven recurrent World Health Organization (WHO) grade II (atypical) or grade III (anaplastic) intracranial supratentorial meningioma; Memorial Sloan-Kettering Cancer Center (MSKCC) central review of histology is not required
History of breast cancer or endometrial cancer confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC) or outside pathology report
Histologic proof of melanoma reviewed and confirmed by Memorial Sloan Kettering Cancer Center (MSKCC)
Advanced renal cell carcinoma of non-clear cell histology with papillary features, histologically confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) pathology; advanced disease is defined as unresectable, locally recurrent disease or metastatic disease; availability of additional tissue for correlative studies is NOT an inclusion requirement
Histologically documented (pathology confirmed at Memorial Sloan-Kettering Cancer Center [MSKCC]), incurable, locally advanced or metastatic solid tumor malignancy, lymphoma, or MPN; the safety-expansion phase will be open to accrual only for patients with MPN
Memorial Sloan Kettering Cancer Center (MSKCC) histologically confirmed ovarian, fallopian tube or primary peritoneal carcinoma
Histologically or cytologically confirmed diagnosis of cancer (including epithelial carcinoma, sarcoma, and melanoma); the diagnosis can be done at Memorial Sloan-Kettering Cancer Center (MSKCC) or at participating institutions
EXPANSION COHORT ONLY: Metastatic or locally advanced unresectable urothelial carcinoma with histologic or cytologic confirmation at Dana-Farber Cancer Institute (DFCI) or Memorial Sloan-Kettering Cancer Center (MSKCC)
Histologically confirmed diagnosis of GCT (nonseminoma or seminoma in men; non-dysgerminomas, dysgerminomas, or germinomas in women or patients with pineal gland GCT) at Memorial Sloan-Kettering Cancer Center (MSKCC) of any primary site (includes female GCT and intracranial GCT)
Pathologic evidence of advanced stage IV or recurrent lung adenocarcinoma reviewed at Memorial Sloan Kettering Cancer Center (MSKCC)
Patient must have pathologically or cytologically Memorial Sloan-Kettering Cancer Center (MSKCC) confirmed esophageal, gastric or gastroesophageal junction (GEJ) adenocarcinoma by the enrolling institution
Memorial Sloan-Kettering Cancer Center (MSKCC)-reviewed pathologically proven diagnosis of primary bladder urothelial carcinoma without evidence of regional (nodal) or distant spread (cT-Ta, Nx or N)
Patients must have adequate access for leukapheresis procedure as assessed by staff from the Memorial Sloan-Kettering Cancer Center (MSKCC) Donor Room
Pathologically confirmed diagnosis of malignant pleural mesothelioma at Memorial Sloan Kettering Cancer Center (MSKCC)
Histologically confirmed muscle invasive transitional cell carcinoma of the bladder at Memorial Sloan-Kettering Cancer Center (MSKCC); (Note: urothelial carcinoma invading into the prostatic stroma with no histologic muscle invasion is allowed, provided the extent of disease is confirmed via imaging and/or exam under anesthesia [EUA])
Patients with breast cancer that is pathologically confirmed at Memorial Sloan Kettering Cancer Center (MSKCC) (pathology from outside institutions is acceptable for the screening phase of the protocol) and defined by the following:\r\n* HER negative (in cases of mixed HER results, the most recent pathology results considered reflective of the active cancer will be considered) \r\n* Previously treated with at least  chemotherapy regimen for metastatic disease and documented progression
Histologically confirmed metastatic head and neck squamous cell carcinoma (HNSCC), including nasopharynx World Health Organization (WHO) type I-III histologies; patients can have simultaneous loco-regional disease; central biopsy review at Memorial Sloan-Kettering Cancer Center (MSKCC) is not required
Lung adenocarcinoma histology confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC)
Pathologic evidence of advanced (non-operable or metastatic) biopsy-proven stage IV or recurrent lung cancer reviewed at Memorial Sloan-Kettering Cancer Center (MSKCC)
Memorial Sloan-Kettering Cancer Center (MSKCC) confirmed diagnosis of multiple myeloma that has relapsed or is resistant after therapy with at least one immunomodulatory drug (i.e. lenalidomide, thalidomide) and at least one proteasome inhibitor
Patients who have undergone T-cell depleted allogeneic hematopoietic stem cell transplantation at Memorial Sloan-Kettering Cancer Center (MSKCC) for:
Patients meeting the following exclusion criteria will be excluded from the functional MRI portion only:\r\n* Metallic implant exclusions will be determined per institutional policies\r\n** Pacemakers and defibrillators are excluded\r\n** Stents etc. will be evaluated according to Memorial Sloan Kettering Cancer Center (MSKCC) policy\r\n* Unmanageable claustrophobia\r\n* High risk for nephrogenic systemic fibrosis
Histologically confirmed intrahepatic cholangiocarcinoma (also variously reported as peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma) (ICC); confirmation of the diagnosis at the Memorial Sloan-Kettering Cancer Center (MSKCC) or at the enrolling institution must be obtained prior to initiation of protocol therapy
Histologically-confirmed metastatic adenocarcinoma of the breast (confirmation will be done at Memorial Sloan Kettering Cancer Center [MSKCC])
History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed at Memorial Sloan Kettering Cancer Center (MSKCC)
Scheduled for partial nephrectomy at Memorial Sloan Kettering Cancer Center (MSKCC) (open or minimally invasive technique) during which renal ischemia is anticipated
Pathologically confirmed recurrent or metastatic advanced solid tumor, for which there is no curative-intent treatment option; pathology confirmation must be performed at Memorial Sloan-Kettering Cancer Center (MSKCC)
A diagnosis of cancer with no restrictions placed on type of cancer, other than that patients with metastatic disease will be excluded; eligibility criteria are not restricted to Memorial Sloan Kettering (MSK) confirmed biopsy/diagnosis; participating institution's testing is sufficient for other study sites
Patients scheduled for radical prostatectomy for the treatment of prostate cancer with one of the consenting surgeons at Memorial Sloan Kettering Cancer Center (MSKCC)
Patients who will receive induction chemotherapy followed by combined chemoradiotherapy at Memorial Sloan-Kettering Cancer Center (MSKCC) for localized stage I-III esophageal or gastroesophageal junction cancer
FOCUS GROUP: IC to a Memorial Sloan Kettering Cancer Center (MSKCC) patient with GBM who died a year or more ago
Histologically or cytologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction (GEJ); pathology must be confirmed at Memorial Sloan Kettering Cancer Center
As per medical record, radical prostatectomy (RP) conducted either at Memorial Sloan-Kettering Cancer Center (MSKCC) or at another institution
Currently a patient of Dr. Christian Nelson at Memorial Sloan Kettering Cancer Center Counseling Center
Pathologically confirmed gastric, gastroesophageal junction (GEJ) or esophageal, adenocarcinoma at either Memorial Sloan-Kettering Cancer Center (MSKCC) or a participating site (biopsy may be performed at other institutions but slides must be confirmed at MSKCC or a participating site, as is routine care at our institution)
Memorial Sloan Kettering Cancer Center (MSK) histologically confirmed early-stage operable breast cancer (patients with HER- negative or HER- positive breast cancer are eligible)
PHASE II: Completed initial surgical consult with breast cancer surgeon at Cancer Institute of New Jersey (CINJ)/Massachusetts General Hospital (MGH)/Memorial Sloan Kettering Cancer Center (MSKCC) and is considering CPM, regardless of the surgical treatment of their primary breast cancer (lumpectomy/mastectomy)
Patient in the Sarcoma, Solid Tumor Gastrointestinal (ST GI), or Thoracic Medicine service at Memorial Sloan Kettering Cancer Center (MSK)
Scheduled to receive anthracycline chemotherapy followed by anti-HER therapy at Memorial Sloan-Kettering Cancer Center (MSKCC)
Histologic diagnosis confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) pathologist as mantle cell lymphoma
Cancer treatment expected plan to include hospitalization for surgical treatment for at least  days at Memorial Sloan-Kettering Cancer Center (MSKCC) as per the patients clinical team
Histologically-confirmed invasive breast cancer by Memorial Sloan-Kettering Cancer Center (MSKCC)
History of non-metastatic breast cancer (ductal carcinoma in situ [DCIS] or stage I, II, or III) as recorded in the medical record at Memorial Sloan-Kettering Cancer Center (MSKCC), by self-report, or by outside correspondence, including a study checklist signed by a physician for patients outside of MSKCC
Memorial Sloan Kettering (MSK) histologically confirmed metastatic breast cancer
Stage - invasive breast cancer that is histologically confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC)
Classified as International Society of Lymphology (ISL) stage II or higher as determined by a Memorial Sloan-Kettering Cancer Center (MSKCC) certified lymphedema therapist (CLT)
Female subjects of childbearing potential must have a negative serum pregnancy test as per Memorial Sloan-Kettering Cancer Center (MSKCC) guidelines
Clinical breast exam interpreted as benign (not suspicious for cancer) at Memorial Sloan Kettering (MSK)
All pathology will be reviewed at Memorial Sloan-Kettering (MSK) to confirm diagnosis
Baseline MP-MRI, which is obtained at Memorial Sloan-Kettering Cancer Center (MSKCC) main campus on the -tesla Philips MRI unit as part of the standard (clinical) staging assessment demonstrates at least one dominant or visible lesion which measures >= . cm in maximum axial diameter as assessed on T-weighted images
Histologically-confirmed (confirmation done at Memorial Sloan-Kettering Cancer Center [MSKCC]) metastatic adenocarcinoma of the breast
Patients selecting treatment outside of Memorial Sloan Kettering (MSK)
Scheduled to undergo surgery at Memorial Sloan-Kettering (MSK)
Planned radical prostatectomy at Memorial Sloan-Kettering Cancer Center (MSKCC)
Patients with history of histologically-confirmed malignant solid tumor (histology confirmed by Memorial Sloan-Kettering Cancer Center [MSKCC] Department of Pathology); NOTE: an exception will be made for patients with brain lesions; patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to histological confirmation
Patients who are already eligible for and are to be treated with hypofractionated or single dose radiation for their spinal lesions\r\n* Note: The patients must have their treatments at Memorial Sloan-Kettering Cancer Center (MSKCC)
Patients with the diagnosis of neuroblastoma must meet both of the following criteria: \r\n* Diagnosis confirmed by histological assessment by Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology or by the presence of bone marrow (BM) metastases PLUS elevated urinary catecholamines\r\n* Relapsed or refractory stage  disease or relapsed or refractory stage v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN)-amplified B or  disease
Histologically confirmed diagnosis of melanoma, breast cancer, or gynecologic cancer at Memorial Sloan-Kettering Cancer Center (MSKCC)
Registered patient at Memorial Sloan-Kettering Cancer Center (MSKCC)
Pathologic confirmation of non-small cell lung cancer (NSCLC) at Memorial Sloan-Kettering Cancer Center (MSKCC)
Patients with history of histologically-confirmed solid malignancy and/or lymphoma (histology confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology)
Patients with (current or past) history of solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma histology confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology
Histologically confirmed diagnosis of melanoma or malignant brain tumor at Memorial Sloan-Kettering Cancer Center (MSKCC)
Patients with histologically-confirmed (confirmation done at Memorial Sloan-Kettering Cancer Center [MSKCC]) malignancies
Histology confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology
Staging imaging workup including a baseline MRI of the prostate and pelvis performed at Memorial Sloan-Kettering Cancer Center (MSKCC)
Women presenting for evaluation at Memorial Sloan-Kettering Cancer Center (MSKCC) with biopsy proven invasive ductal cancer (IDC) or invasive lobular cancer (ILC)
Patients with histologically confirmed prostate cancer at Memorial Sloan-Kettering Cancer Center (MSKCC)
Patients with primary locally advanced rectal adenocarcinoma (- cm from the anal verge) confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) pathologist and eligible to undergo chemoradiation and surgical resection at MSKCC
Radiographically resectable PDAC as adjudicated by Memorial Sloan-Kettering Cancer Center (MSKCC) surgical oncologist without evidence of distant metastases by computed tomography (CT) or by laparoscopy, if performed at the discretion of the surgeon*
Be seen regularly (at least monthly) at a Memorial Sloan-Kettering Cancer Center (MSKCC) gastrointestinal (GI) medical oncology clinic
All Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic scores allowed
